Vanguard Group
CAMP icon

Vanguard Group’s CAMP4 Therapeutics CAMP Stock Holding History

Vanguard Group’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.3M Buy
1,672,960
+1,359,454
+434% +$5.78M ﹤0.01% 2956
2025
Q3 		$941K Sell
313,506
-15,385
-5% -$28.5K ﹤0.01% 3808
2025
Q2 		$477K Buy
328,891
+95,058
+41% +$189K ﹤0.01% 3931
2025
Q1 		$935K Buy
233,833
+45,917
+24% +$222K ﹤0.01% 3732
2024
Q4 		$981K Buy
+187,916
New +$1.54M ﹤0.01% 3770

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Vanguard Group's CAMP Position: Q4 2025 in Review

Vanguard Group increased its CAMP4 Therapeutics (CAMP) stake by 434% in Q4 2025, buying an estimated $5.78M and bringing the position to 1,672,960 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2956.

Vanguard Group first reported a position in CAMP in Q4 2024 and has held it in 5 quarters since. 40 funds tracked by Wall St. Rank hold CAMP as of Q4 2025.

  • Vanguard Group held 1,672,960 shares of CAMP4 Therapeutics worth $10.3M as of Q4 2025.
  • Vanguard Group bought 1,359,454 CAMP4 Therapeutics shares in Q4 2025, an estimated $5.78M.
  • CAMP4 Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2956 holding.
  • Vanguard Group first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 40 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.